CHMP Fast-Tracks BMS' Empliciti Nod
This article was originally published in Scrip
Bristol-Myers Squibb and AbbVie's novel treatment for multiple myeloma, Empliciti (elotuzumab), is set for EU approval after a speedy positive opinion from the CHMP. The development follows an earlier than expected approval at the US FDA last November for the same indication.
You may also be interested in...
The market opportunity in the EU for Alexion’s Soliris has increased following European Commission approval of the additional indication, NMOSD. The EU indications for Bristol-Myers Squibb’s Empliciti have been extended to include use with pomalidomide and dexamethasone in a triplet combination for relapsed and refractory multiple myeloma.
The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to In Vivo about what’s coming next from the UK major’s cancer pipeline.